No Data
No Data
An Xu Biotech: Mainly drug testing and infectious disease testing products after COVID-19 | Direct performance report
① “After the demand for COVID-19 testing declined, the company's products are currently mainly drug testing products and infectious disease testing products.” ② In the future, An Xu Biotech will also need to address at least two aspects of single addiction, including excessive reliance on overseas income and a single dependency on product income.
Assure Tech (Hangzhou) (SHSE:688075) Could Be Struggling To Allocate Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. Firstly, we'd want to identify a growing return on capital employ
Express News | Anxu Biotech: Net profit of 70.198 million yuan in the first quarter increased 38.09% year-on-year
Anxu Biotech (688075.SH): Net profit in 2023 fell 95.34% year on year
Gelonghui, Feb. 28, 丨 An Xu Biotech (688075.SH) announced its 2023 annual performance report. During the reporting period, the company achieved operating income of 508.2998 million yuan, a decrease of 91.76% over the same period of the previous year; realized net profit attributable to owners of the parent company of 141.7741 million yuan, a decrease of 95.34% over the same period last year; realized net profit attributable to owners of the parent company after deducting non-recurring profit and loss of 52.44,800 yuan, a decrease of 98.24% from the same period last year.
Insiders Are the Top Stockholders in Assure Tech (Hangzhou) Co., Ltd. (SHSE:688075), and the Recent 13% Drop Might Have Disappointed Them
Key Insights Insiders appear to have a vested interest in Assure Tech (Hangzhou)'s growth, as seen by their sizeable ownership The top 2 shareholders own 52% of the company Using data from company
Anxu Biotech (688075.SH): 2023 net profit pre-reduced by 94.98% to 95.82%
Gelonghui, January 30丨An Xu Biotech (688075.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, it is expected to achieve net profit of 127.3982 million yuan to 152.887 million yuan in 2023. Compared with the same period last year (statutory disclosure data), it will decrease by 2891.754 million yuan to 2917.2751 million yuan, a year-on-year decrease of 94.98% to 95.82%. Net profit attributable to the owner of the parent company after deducting non-recurring profit and loss is expected to be 5,209.31 in 2023
No Data